Cargando…

Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve

PURPOSE: This study investigated the impact of baseline clinical and optical coherence tomography (OCT) factors on the response to a 0.19-mg fluocinolone acetonide (FAc) implant in patients with noninfectious uveitic macular edema evaluated by the area under the curve over 24 months. METHODS: A retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Lucy Joanne, Auffarth, Gerd Uwe, Khoramnia, Ramin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516239/
https://www.ncbi.nlm.nih.gov/pubmed/37384926
http://dx.doi.org/10.1089/jop.2023.0027
_version_ 1785109096015331328
author Kessler, Lucy Joanne
Auffarth, Gerd Uwe
Khoramnia, Ramin
author_facet Kessler, Lucy Joanne
Auffarth, Gerd Uwe
Khoramnia, Ramin
author_sort Kessler, Lucy Joanne
collection PubMed
description PURPOSE: This study investigated the impact of baseline clinical and optical coherence tomography (OCT) factors on the response to a 0.19-mg fluocinolone acetonide (FAc) implant in patients with noninfectious uveitic macular edema evaluated by the area under the curve over 24 months. METHODS: A retrospective study was conducted of eyes of patients with noninfectious uveitic macular edema undergoing FAc treatment, with follow-up from baseline to 24 months. The area under the curve (AUC) of best-corrected visual acuity (BCVA) and the central macular thickness (CMT) were calculated using the trapezoidal rule. Clinical and OCT data at the time of FAc administration were collected, and associations with AUC of BCVA and CMT changes were investigated. RESULTS: Twenty-three patients were enrolled. BCVA and CMT significantly improved after FAc implantation (P < 0.05). AUC(BCVA) and AUC(CMT) were 0.41 ± 0.33 logarithm of minimal angle of resolution/6 months and 320.15 ± 321.64 μm/6 months, respectively. Better baseline BCVA (coefficient [coef.] = 0.83, P < 0.001) and macular thickness reduction after FAc administration (coef. = −0.0001, P < 0.05) were associated with better BCVA after FAc treatment. In contrast, baseline OCT biomarkers such as ellipsoid zone reflectivity and choroidal vascularity index, sex, or disease duration before FAc injection showed no correlation with AUC(BCVA) and AUC(CMT) (P > 0.05). The younger the patient at the time of FAc injection, the greater the reduction in CMT (coef. = 1.76, P < 0.05). CONCLUSIONS: Among all clinical and morphological baseline factors, Baseline BCVA was the strongest predictor for AUC(BCVA), while no association with baseline OCT features was observed. Overall, improvement of BCVA and CMT after FAc injection was maintained over 24 months. This study is registered in the German Clinical Trials Register under the DRKS-ID: DRKS00024399.
format Online
Article
Text
id pubmed-10516239
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-105162392023-09-23 Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve Kessler, Lucy Joanne Auffarth, Gerd Uwe Khoramnia, Ramin J Ocul Pharmacol Ther Original Articles PURPOSE: This study investigated the impact of baseline clinical and optical coherence tomography (OCT) factors on the response to a 0.19-mg fluocinolone acetonide (FAc) implant in patients with noninfectious uveitic macular edema evaluated by the area under the curve over 24 months. METHODS: A retrospective study was conducted of eyes of patients with noninfectious uveitic macular edema undergoing FAc treatment, with follow-up from baseline to 24 months. The area under the curve (AUC) of best-corrected visual acuity (BCVA) and the central macular thickness (CMT) were calculated using the trapezoidal rule. Clinical and OCT data at the time of FAc administration were collected, and associations with AUC of BCVA and CMT changes were investigated. RESULTS: Twenty-three patients were enrolled. BCVA and CMT significantly improved after FAc implantation (P < 0.05). AUC(BCVA) and AUC(CMT) were 0.41 ± 0.33 logarithm of minimal angle of resolution/6 months and 320.15 ± 321.64 μm/6 months, respectively. Better baseline BCVA (coefficient [coef.] = 0.83, P < 0.001) and macular thickness reduction after FAc administration (coef. = −0.0001, P < 0.05) were associated with better BCVA after FAc treatment. In contrast, baseline OCT biomarkers such as ellipsoid zone reflectivity and choroidal vascularity index, sex, or disease duration before FAc injection showed no correlation with AUC(BCVA) and AUC(CMT) (P > 0.05). The younger the patient at the time of FAc injection, the greater the reduction in CMT (coef. = 1.76, P < 0.05). CONCLUSIONS: Among all clinical and morphological baseline factors, Baseline BCVA was the strongest predictor for AUC(BCVA), while no association with baseline OCT features was observed. Overall, improvement of BCVA and CMT after FAc injection was maintained over 24 months. This study is registered in the German Clinical Trials Register under the DRKS-ID: DRKS00024399. Mary Ann Liebert, Inc., publishers 2023-09-01 2023-09-15 /pmc/articles/PMC10516239/ /pubmed/37384926 http://dx.doi.org/10.1089/jop.2023.0027 Text en © Lucy Joanne Kessler et al., 2023; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Kessler, Lucy Joanne
Auffarth, Gerd Uwe
Khoramnia, Ramin
Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
title Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
title_full Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
title_fullStr Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
title_full_unstemmed Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
title_short Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
title_sort functional and morphological responses to fluocinolone acetonide 0.19 mg in noninfectious uveitic macular edema evaluated as the area-under-the-curve
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516239/
https://www.ncbi.nlm.nih.gov/pubmed/37384926
http://dx.doi.org/10.1089/jop.2023.0027
work_keys_str_mv AT kesslerlucyjoanne functionalandmorphologicalresponsestofluocinoloneacetonide019mginnoninfectiousuveiticmacularedemaevaluatedastheareaunderthecurve
AT auffarthgerduwe functionalandmorphologicalresponsestofluocinoloneacetonide019mginnoninfectiousuveiticmacularedemaevaluatedastheareaunderthecurve
AT khoramniaramin functionalandmorphologicalresponsestofluocinoloneacetonide019mginnoninfectiousuveiticmacularedemaevaluatedastheareaunderthecurve